Circ_0001175 Promotes Hepatocellular Carcinoma Cell Proliferation and Metastasis by Regulating miR-130a-5p.
HCC
circ_0001175
metastasis
miR-130a-5p
proliferation
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
05
2020
accepted:
12
11
2020
entrez:
7
1
2021
pubmed:
8
1
2021
medline:
8
1
2021
Statut:
epublish
Résumé
Many aberrantly expressed circular RNAs (circRNAs) play important roles in the development and progression of hepatocellular carcinoma (HCC). However, the exact function of circ_0001175 in HCC cells is unknown. Our study aimed to investigate the expression characteristics of circ_0001175 in HCC and its effects on the proliferation, migration and invasion of HCC cells, and to explore the potential mechanism. Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot were carried out to detect circ_0001175, microRNA-130a-5p (miR-130a-5p) and Circ_0001175 and Circ_0001175 is highly expressed in HCC and facilitates HCC progression through regulating miR-130a-5p/
Identifiants
pubmed: 33408482
doi: 10.2147/OTT.S262408
pii: 262408
pmc: PMC7781360
doi:
Types de publication
Journal Article
Langues
eng
Pagination
13315-13327Informations de copyright
© 2020 Li et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest for this work.
Références
Eur Rev Med Pharmacol Sci. 2019 Sep;23(18):7848-7854
pubmed: 31599409
Mol Ther Nucleic Acids. 2020 Mar 6;19:228-239
pubmed: 31846800
Cells. 2019 Dec 03;8(12):
pubmed: 31816923
Life Sci. 2020 Jan 15;241:117166
pubmed: 31843527
Eur Rev Med Pharmacol Sci. 2019 Jan;23(1):241-252
pubmed: 30657566
Artif Cells Nanomed Biotechnol. 2020 Dec;48(1):197-205
pubmed: 31851829
Cell Prolif. 2019 Sep;52(5):e12635
pubmed: 31334580
Mol Oncol. 2020 Feb;14(2):447-461
pubmed: 31758671
Cancer Sci. 2012 Jul;103(7):1356-62
pubmed: 22486813
Cancer Lett. 2019 Sep 28;460:18-28
pubmed: 31207321
Cell Death Dis. 2019 Nov 6;10(11):843
pubmed: 31695022
Cell Death Dis. 2019 Dec 10;10(12):945
pubmed: 31822654
Scand J Gastroenterol. 2019 Feb;54(2):240-245
pubmed: 30880503
Ann Transl Med. 2019 Oct;7(20):577
pubmed: 31807558
Can J Gastroenterol Hepatol. 2018 Jun 3;2018:4756147
pubmed: 29974040
Eur Rev Med Pharmacol Sci. 2019 Dec;23(23):10264-10273
pubmed: 31841181
Cancer Res. 2018 Aug 1;78(15):4150-4162
pubmed: 29844124
Mol Genet Genomic Med. 2020 Feb;8(2):e1093
pubmed: 31845519
Cancer Manag Res. 2019 Oct 24;11:9133-9143
pubmed: 31695501
Oncogene. 2020 Mar;39(10):2140-2155
pubmed: 31819169
Cell Cycle. 2019 Nov;18(21):2939-2953
pubmed: 31522588
Ann Surg Oncol. 2015 Jul;22(7):2253-61
pubmed: 25490872
Front Oncol. 2019 Nov 29;9:1242
pubmed: 31850191
World J Gastroenterol. 2016 Aug 7;22(29):6582-94
pubmed: 27547002
Med Oncol. 2014 Oct;31(10):230
pubmed: 25218269
Clin Cancer Res. 2019 Feb 1;25(3):912-920
pubmed: 30274981
Cell Death Dis. 2019 Sep 10;10(9):658
pubmed: 31506425
Cell Death Dis. 2018 Oct 25;9(11):1091
pubmed: 30361504
Onco Targets Ther. 2019 Nov 05;12:9201-9213
pubmed: 31807004
J Cell Mol Med. 2020 Jan;24(2):1437-1450
pubmed: 31851778
Aging (Albany NY). 2019 May 28;11(10):3362-3375
pubmed: 31137016
Oncogene. 2009 Oct 8;28(40):3526-36
pubmed: 19617899
Oncogene. 2019 Apr;38(15):2844-2859
pubmed: 30546088
Cancer Biomark. 2018;21(4):859-868
pubmed: 29439311
Onco Targets Ther. 2018 Oct 25;11:7503-7512
pubmed: 30498363
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Front Oncol. 2019 Nov 29;9:1293
pubmed: 31850200
Small. 2018 Jan;14(1):
pubmed: 29148623
Am J Cancer Res. 2019 Aug 01;9(8):1695-1707
pubmed: 31497351
HPB (Oxford). 2019 Jun;21(6):731-738
pubmed: 30391218
J Cancer. 2019 Jun 2;10(13):2942-2952
pubmed: 31281471